Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621001235897
Ethics application status
Approved
Date submitted
10/08/2021
Date registered
13/09/2021
Date last updated
2/05/2022
Date data sharing statement initially provided
13/09/2021
Date results information initially provided
20/04/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of an Inhaled Antibody in Healthy Volunteers
Query!
Scientific title
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of Nebulized IN-006 in Healthy Volunteers
Query!
Secondary ID [1]
304480
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COVID-19
322314
0
Query!
Condition category
Condition code
Respiratory
319983
319983
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
319984
319984
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is a single centre, double-blind randomised placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of nebulised IN-006 in healthy volunteers.
The study will be enrolled in 3 cohorts. Subjects will only be allowed to enrol in one cohort.
1. 2 cohorts of single-ascending dose (SAD) cohorts: The first cohort will enrol 8 subjects, randomised to receive a single low dose of IN-006 or placebo. In the second cohort, 8 subjects will be randomised to receive a single high dose of IN-006 or placebo.
2. The last cohort is a multiple-dose (MD) cohort where 8 subjects will be randomised to receive a daily dose of IN-006 or placebo for 7 days. The dose will be determined from the safety data from SAD.
All subjects will receive IN-006 or placebo via a nebulizer which will be administered by the study site staff while in the clinic.
A Dose Escalation Committee (DEC) will review the safety data of the first 24 hours of SAD Cohort 1 before proceeding to SAD Cohort 2. A second DEC meeting will review safety data through Day 8 of Cohort 1 and the first 24 hours of SAD COhort 2 to determine the dose that will be administered in the MD cohort.
Query!
Intervention code [1]
320829
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo will be 0.9% normal saline and will be administered via a nebulizer by the study site staff in the identical manner as IN-006.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
327859
0
The primary objective is to evaluate the safety and tolerability of nebulized IN-006 in healthy volunteers following a single dose of IN-006.
Safety and tolerability assessments will include vital signs (including FEV1 and SpO2), safety labs, ECG, and physical exams.
Query!
Assessment method [1]
327859
0
Query!
Timepoint [1]
327859
0
Vital signs including FEV1 and SpO2 will be collected at:
Screening, Day -1 (the day prior to dosing), Dosing Day 1, Day 2 at 24 hours post-dose, Day 4 (72 hr), Day 6 (120 hr), Day 8 (168 hr), Day 15, and Day 29 (End Of Study [EOS]). Vitals signs will be measured by an automated blood pressure machine. FEV1 will be measured by standard spirometry and SpO2 will be measured by a pulse oximeter.
Safety labs will be collected at:
Screening, Day -1 (the day prior to dosing), and post-dose on Day 2 (24 hours post-dose), Day 8 (168 hrs), and Day 29 (EOS).
ECGs will be collected at Screening, Day -1 (the day prior to dosing), Day 2 (24 hours post-dose), and Day 29 (EOS),
Complete physical exams will be completed at Screening, Day 2 (24 hours post-dose), and Day 29 (EOS), Symptom-directed exams may be conducted at any other time at the discretion of the investigator.
Query!
Primary outcome [2]
328198
0
The primary objective is to evaluate the safety and tolerability of nebulized IN-006 in healthy volunteers following multiple doses of IN-006.
Safety and tolerability assessments will include vital signs (including FEV1 and SpO2), safety labs, ECG, and physical exams.
Query!
Assessment method [2]
328198
0
Query!
Timepoint [2]
328198
0
Vital signs including FEV1 and SpO2 will be collected at:
Screening, Day -1 (the day prior to dosing), Dosing Days 1 through 7, Day 8, Day 15, and Day 29 (EOS). Vitals signs will be measured by an automated blood pressure machine. FEV1 will be measured by standard spirometry and SpO2 will be measured by a pulse oximeter.
Safety labs will be collected at:
Screening, Day -1, and post-dose on Day 4 (72 hrs), Day 8 (168 hrs), Day 15, and Day 29.
ECGs will be collected at Screening, Day -1 (the day prior to dosing), and post-dose on Day 8, and Day 29 (EOS),
Complete physical exams will be completed at Screening, Day 8, and Day 29 (EOS), Symptom-directed exams may be conducted at any other time at the discretion of the investigator
Query!
Secondary outcome [1]
396795
0
To assess the pharmacokinetics of IN-006 levels in serum after a single dose of IN-006. PK parameters to be assessed will include Cmax, AUC, tmax , and t1/2.
Query!
Assessment method [1]
396795
0
Query!
Timepoint [1]
396795
0
On Day 1, predose and 30 minutes, 3 hours, and 12 hours post-dose, Day 2 (24 hours post-dose), and on Days 4, 6, 8, 15, and 29.
Query!
Secondary outcome [2]
396796
0
To assess the anti-drug-antibody levels induced against IN-006 after a single dose of IN-006. Samples will be analyzed using serum blood.
Query!
Assessment method [2]
396796
0
Query!
Timepoint [2]
396796
0
On Day 1 predose, and post-dose on Day 8 and Day 29.
Query!
Secondary outcome [3]
396797
0
To assess the pharmacokinetics of IN-006 in the respiratory tract (nasal fluids) after a single dose of IN-006. PK parameters to be assessed will include Cmax, AUC, tmax , and t1/2.
Query!
Assessment method [3]
396797
0
Query!
Timepoint [3]
396797
0
On Day 1, predose and 3 hours post-dose, Day 2 (24 hours post-dose); and on Days 4, 6, and 8.
Query!
Secondary outcome [4]
396798
0
To assess the pharmacokinetics of IN-006 levels in serum after multiple doses of IN-006. PK parameters to be assessed will include Cmax, AUC, tmax , and t1/2.
Query!
Assessment method [4]
396798
0
Query!
Timepoint [4]
396798
0
On Day 1 predose, 30 minutes, 3 hours, and 12 hours post-dose, Day 2 (24 hours post-dose of Day 1); D5 pre-dose, Day 7 at 30 minutes, 3 hours, and 12 hours post-dose, Day 8 (24 hours post-dose of Day 7); and on Days 10, 15, 22, and 29.
Query!
Secondary outcome [5]
396799
0
To assess the anti-drug-antibody levels induced against IN-006 after multiple doses of IN-006. Samples will be analyzed using serum blood.
Query!
Assessment method [5]
396799
0
Query!
Timepoint [5]
396799
0
At Day 1 predose, and post-dose on Days 15 and 29.
Query!
Secondary outcome [6]
396800
0
To assess the pharmacokinetics of IN-006 in the respiratory tract (nasal fluids) after multiple doses of IN-006. PK parameters to be assessed will include Cmax, AUC, tmax , and t1/2.
Query!
Assessment method [6]
396800
0
Query!
Timepoint [6]
396800
0
On Day 1 predose and 3 hours post-dose , Day 2 (24 hours post-dose of Day 1), Day 5 pre-dose, Day 7 at 3 hours post-dose, Day 8 (24 hours post-dose of Day 7), and on Days 10, 15, 22, and 29.
Query!
Eligibility
Key inclusion criteria
1. Male and female, age 18-55 years, inclusive.
2. Non-smoker or smokes on average less than or equal to 10 cigarettes per week
3. Woman participants must be non-pregnant and either surgically sterile, use an acceptable contraceptive method, or be post-menopausal
4. Male participants must be surgically sterile, abstinent, or if engaged in sexual relations with a WOCBP, the partner must be surgically sterile or using an acceptable contraceptive method
5. Negative SARS-CoV-2 RT-PCR nasal swab during screening period
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Known or suspected symptomatic viral infection within 14 days of dosing initiation.
2. Signs of active pulmonary infection or pulmonary inflammatory conditions within 14 days of dosing.
3. History of hypersensitivity or allergies to a biologic drug or a constituent of the study drug or placebo.
4. History of previous administration of a monoclonal antibody or any inhaled biologic.
5. History of vaccination against SARS-CoV-2.
6. History of atopy or airway hyperresponsiveness.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A computerised randomisation list will be created by an unbinded statistician or designee. Subjects will be randomised to receive IN-006 or placebo in a ratio of 3 to 1 respectively.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
In each cohort; 8 participants will be enrolled. Participants in each cohort will be randomized 3:1 to receive nebulized IN-006 or placebo.
Block randomization will also be used in the SAD portions of the study to allow randomization of a sentinel pair (1 active, 1 placebo) to be dosed first within each SAD dose group. The sentinel’s dosing and early post-dosing course will precede that of the remainder of the dose group, which will be randomized 1 placebo to 5 active; dosing of the remainder group will be done after the PI or DEC decides to proceed with dosing after an observation period of the sentinel group.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
SAD and Multiple Dose cohorts.
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Treatment effects will be examined using 2-sided tests at an alpha level of 0.05. No adjustment for multiplicity will be performed in this study. Details of the handling of dropouts or missing data will be fully described in the statistical analysis plan (SAP).
Additional exploratory analyses of the data will be conducted as deemed appropriate. The SAP will be finalized prior to database lock, and it will include a more technical and detailed description of the statistical analyses described in this section.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
13/09/2021
Query!
Actual
22/09/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
3/12/2021
Query!
Date of last data collection
Anticipated
Query!
Actual
29/12/2021
Query!
Sample size
Target
24
Query!
Accrual to date
Query!
Final
23
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
19737
0
Nucleus Network - Melbourne
Query!
Recruitment postcode(s) [1]
34376
0
3004 - Melbourne
Query!
Funding & Sponsors
Funding source category [1]
308841
0
Commercial sector/Industry
Query!
Name [1]
308841
0
Inhalon Biopharma, Inc.
Query!
Address [1]
308841
0
104 TW Alexander Drive
Building 20, Room 2021
Durham, NC 27709
Query!
Country [1]
308841
0
United States of America
Query!
Funding source category [2]
309162
0
Government body
Query!
Name [2]
309162
0
United States Department of Defense
Query!
Address [2]
309162
0
MTEC c/o ATI
315 Sigma Drive
Summerville, SC 29486
Query!
Country [2]
309162
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Inhalon Biopharma, Inc.
Query!
Address
104 TW Alexander Drive
Building 20, Room 2021
Durham, NC 27709
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
310059
0
Commercial sector/Industry
Query!
Name [1]
310059
0
Inhalon Biopharma Pty Ltd
Query!
Address [1]
310059
0
58 Gipps Street
Collingwood, VIC 3066
Query!
Country [1]
310059
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
308748
0
Alfred Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
308748
0
Old Baker Building
Level 1
55 COmmercial Road
Melbourne, VIC 3004
Query!
Ethics committee country [1]
308748
0
Australia
Query!
Date submitted for ethics approval [1]
308748
0
26/06/2021
Query!
Approval date [1]
308748
0
26/07/2021
Query!
Ethics approval number [1]
308748
0
Query!
Summary
Brief summary
This Phase 1a study will be a randomized, placebo-controlled, double-blind, single-center, ascending dose, first in human trial of an inhaled antibody vs. placebo in normal, healthy volunteer (NHV) men and women. The study will assess safety and pharmacokinetics, in initial single ascending doses (SAD) portion, followed by a multiple dose cohort..
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
111754
0
Dr Jason Lickliter
Query!
Address
111754
0
Nucleus Network
Level 5, Burnet Tower, 89
Commercial Road, Melbourne,
VIC 3004
Query!
Country
111754
0
Australia
Query!
Phone
111754
0
+61 3 8593 9860
Query!
Fax
111754
0
Query!
Email
111754
0
[email protected]
Query!
Contact person for public queries
Name
111755
0
Mr Taylor Kilfoil
Query!
Address
111755
0
InClin Pty Ltd
Suite 210, 25/29 Berry Street
Sydney, NSW 2060
Query!
Country
111755
0
Australia
Query!
Phone
111755
0
+61 408 880 403
Query!
Fax
111755
0
Query!
Email
111755
0
[email protected]
Query!
Contact person for scientific queries
Name
111756
0
Mr Taylor Kilfoil
Query!
Address
111756
0
InClin Pty Ltd
Suite 210, 25/29 Berry Street
Sydney, NSW 2060
Query!
Country
111756
0
Australia
Query!
Phone
111756
0
+61 408 880 403
Query!
Fax
111756
0
Query!
Email
111756
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
The information developed during the conduct of this clinical study is considered confidential by the sponsor. This information may be disclosed as deemed necessary by the sponsor, except as required by law or regulation. Data from all subjects participating in the study will be pooled and analyzed by the sponsor or their designee. Individual participant data will not be published or made publicly available in a way that is identifiable, except as required by law or regulation.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF